Literature DB >> 35103898

Incremental prognostic value of arterial elastance in mild-to-moderate idiopathic pulmonary fibrosis.

Andrea Sonaglioni1, Antonella Caminati2, Gian Luigi Nicolosi3, Michele Lombardo1, Sergio Harari4,5.   

Abstract

Previous reports suggested that poor pulmonary function was associated with increased arterial elastance (Ea) in patients with chronic obstructive pulmonary disease and systemic sclerosis. The mechanisms connecting pulmonary function and Ea have not yet been accurately studied in patients with idiopathic pulmonary fibrosis (IPF). The present study was designed to assess Ea in IPF patients without chronic severe pulmonary hypertension and to determine its prognostic role over a medium-term follow-up. This retrospective study included 60 consecutive patients with mild-to-moderate IPF (73.8 ± 6.6 years, 75% males) and 60 controls matched by age, sex and cardiovascular risk factors. All patients underwent physical examination, spirometry, blood tests, modified Haller index (MHI, chest transverse diameter over the distance between sternum and spine) assessment, conventional transthoracic echocardiography implemented with speckle tracking analysis of left atrial positive global strain (LA-GSA+ ) and finally carotid Doppler ultrasonography, at basal evaluation. The effective arterial elastance index (EaI) was calculated as the ratio of end-systolic pressure to stroke volume index. During follow-up period, we evaluated the composite endpoint of (1) pulmonary or cardiovascular hospitalizations; (2) all-cause mortality. At baseline, EaI was significantly higher in IPF patients than controls (4.1 ± 1.3 vs 3.5 ± 1.0 mmHg/ml/m2, p = 0.01). EaI was strongly correlated to the following variables: C-reactive protein (CRP) (r = 0.86), forced vital capacity (FVC) (r =  - 0.91), E/e' ratio (r = 0.91), LA-GSA+  (r =  - 0.92), common carotid artery-cross sectional area (CCA-CSA) (r = 0.89) and MHI (r = 0.86), in IPF patients. Mean follow-up time was 2.4 ± 1.3 years. During follow-up, 12 patients died and 17 were hospitalized due to major adverse clinical events. At univariate Cox analysis, CRP (HR 1.51, 95% CI 1.25-1.82), FVC (HR 0.88, 95% CI 0.85-0.91), LA-GSA+  (HR 0.85, 95% CI 0.77-0.94), CCA-CSA (HR 1.12, 95% CI 1.03-1.22) and EaI (HR 2.43, 95% CI 1.75-3.37) were significantly associated with outcome. At multivariate Cox analysis, only EaI (HR 1.60, 95% CI 1.03-2.50) retained statistical significance. An EaI ≥ 4 mmHg/ml/m2 showed 100% sensitivity and 99.4% specificity for predicting outcome (AUC = 0.98). In patients with mild-to-moderate IPF, an EaI ≥ 4 mmHg/ml/m2 is a negative prognostic factor over a medium-term follow-up.
© 2022. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  C-reactive protein; Cardiovascular disease; Interstitial lung disease; Outcome; Prognosis; Pulmonary hypertension

Year:  2022        PMID: 35103898     DOI: 10.1007/s10554-022-02541-y

Source DB:  PubMed          Journal:  Int J Cardiovasc Imaging        ISSN: 1569-5794            Impact factor:   2.357


  49 in total

1.  Contribution of systemic vascular resistance and total arterial compliance to effective arterial elastance in humans.

Authors:  Denis Chemla; Isabelle Antony; Yves Lecarpentier; Alain Nitenberg
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-04-10       Impact factor: 4.733

2.  Risk factors for cardiovascular disease in people with idiopathic pulmonary fibrosis: a population-based study.

Authors:  William Dalleywater; Helen A Powell; Richard B Hubbard; Vidya Navaratnam
Journal:  Chest       Date:  2015-01       Impact factor: 9.410

3.  All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.

Authors:  Talmadge E King; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Roland M du Bois; Jonathan A Leff; Steven D Nathan; Steven A Sahn; Dominique Valeyre; Paul W Noble
Journal:  Am J Respir Crit Care Med       Date:  2014-04-01       Impact factor: 21.405

Review 4.  The clinical impact of major comorbidities on idiopathic pulmonary fibrosis.

Authors:  Atsushi Suzuki; Yasuhiro Kondoh
Journal:  Respir Investig       Date:  2017-01-14

Review 5.  Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue.

Authors:  Antonella Caminati; Chiara Lonati; Roberto Cassandro; Davide Elia; Giuseppe Pelosi; Olga Torre; Maurizio Zompatori; Elisabetta Uslenghi; Sergio Harari
Journal:  Eur Respir Rev       Date:  2019-10-01

Review 6.  Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities.

Authors:  Christopher S King; Steven D Nathan
Journal:  Lancet Respir Med       Date:  2016-09-03       Impact factor: 30.700

7.  Epidemiology of idiopathic pulmonary fibrosis: a population-based study in primary care.

Authors:  Sergio Harari; Michele Davì; Alice Biffi; Antonella Caminati; Alessandra Ghirardini; Valeria Lovato; Claudio Cricelli; Francesco Lapi
Journal:  Intern Emerg Med       Date:  2019-09-20       Impact factor: 3.397

Review 8.  The Ventricular-Arterial Coupling: From Basic Pathophysiology to Clinical Application in the Echocardiography Laboratory.

Authors:  Francesco Antonini-Canterin; Stefano Poli; Olga Vriz; Daniela Pavan; Vitantonio Di Bello; Gian Luigi Nicolosi
Journal:  J Cardiovasc Echogr       Date:  2013 Oct-Dec

Review 9.  Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management.

Authors:  Johan van Cleemput; Andrea Sonaglioni; Wim A Wuyts; Monica Bengus; John L Stauffer; Sergio Harari
Journal:  Adv Ther       Date:  2018-12-15       Impact factor: 3.845

10.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.